Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17774713 | 0.89 | ALDH1A1 (0.64) | ALDH1A1TDP1HSD17B10CASP1CASP7 | |
| SCHEMBL6175983 | 0.81 | CSNK2A1 (0.50) | ALDH1A1HSD17B10KDM4EKMT2AMEN1 | |
| SCHEMBL14458139 | 0.81 | MEN1 (0.48) | ALDH1A1TDP1HSD17B10CASP1CASP7 | |
| SCHEMBL6175731 | 0.79 | AKR1C3 (0.64) | ALDH1A1HSD17B10KDM4EKMT2AMEN1 | |
| SCHEMBL2227236 | 0.79 | HMGB1 (0.58) | ALDH1A1TDP1HSD17B10CASP1CASP7 | |
| SCHEMBL29581860 | 0.79 | HMGB1 (0.58) | ALDH1A1TDP1HSD17B10CASP1CASP7 | |
| SCHEMBL11302359 | 0.79 | TTR (0.41) | ALDH1A1HSD17B10KDM4EKMT2AMEN1 | |
| SCHEMBL6175690 | 0.79 | KEAP1 (0.42) | ALDH1A1HSD17B10KDM4EKMT2AMEN1 | |
| SCHEMBL6175638 | 0.79 | AKR1C2 (0.64) | ALDH1A1HSD17B10CASP1KDM4EKMT2A | |
| SCHEMBL11569683 | 0.79 | GAA (0.51) | ALDH1A1TDP1HSD17B10CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956647-B2 | Pellet formulation for the treatment of the intestinal tract | DR. FALK PHARMA GMBH (DE) | 2015-02-17 | — | — | US | claimed |
| US-8911778-B2 | Pellet formulation for the treatment of the intestinal tract | DR. FALK PHARMA GMBH (DE) | 2014-12-16 | — | — | US | claimed |
| US-8496965-B2 | Pellet formulation for the treatment of the intenstinal tract | DR. FALK PHARMA GMBH (DE) | 2013-07-30 | — | — | US | claimed |
| US-20130177650-A1 | PELLET FORMULATION FOR THE TREATMENT OF THE INTESTINAL TRACT | DR. FALK PHARMA GMBH | 2013-07-11 | — | — | US | claimed |
| US-20120308659-A1 | PELLET FORMULATION FOR THE TREATMENT OF THE INTENSTINAL TRACT | OTTERBECK NORBERT (DE) | 2012-12-06 | — | — | US | claimed |
| JP-5066221-A | — | — | None | — | — | JP | disclosed |
| US-20250146074-A1 | DETERMINING WHETHER AN IBD PATIENT WILL RESPOND TO 5-ASA THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-116270547-A | Mesalamine enteric sustained-release preparation and preparation method thereof | 甘李药业股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | NOGRA PHARMA LIMITED (IE) | 2020-07-30 | — | — | US | disclosed |
| US-10473669-B2 | Methods for treating inflammatory bowel disease | NOGRA PHARMA LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION | 2019-04-18 | — | — | US | disclosed |
| EP-3355896-A2 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | Nogra Pharma Limited (IE) | 2018-08-08 | — | — | EP | disclosed |
| WO-2008063211-A2 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080096849-A1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070265232-A1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070167416-A1 | Administering 5-aminosalicylate (balsalazide) with food increases bioavailability; label on container recommends to take drug with food; inflammatory bowel disease, radiation enteritis, colon cancer; gastrointestinal disorders | BAUSCH HEALTH US, LLC | 2007-07-19 | — | — | US | disclosed |
| JP-H0566221-A | METHOD FOR MEASURING CONCENTRATION OF METABOLIC MATERIAL OF SALAZOSULFAPYRIDINE IN BLOOD | GREEN CROSS CORP:THE | 1993-03-19 | — | — | JP | disclosed |
| EP-0393104-B1 | MEASUREMENT OF PGE 2 (PROSTAGLANDIN E 2) LEVELS IN PATIENTS WITH CHRONIC INFLAMMATORY BOWEL DISEASE | FONDEN FOR PROSTAGLANDINFORSKNING (DK) | 1992-07-15 | — | — | EP | disclosed |
| EP-0393104-A1 | MEASUREMENT OF PGE 2 (PROSTAGLANDIN E 2) LEVELS IN PATIENTS WITH CHRONIC INFLAMMATORY BOWEL DISEASE. | FONDEN FOR PROSTAGLANDINFORSKN (DK) | 1990-10-24 | — | — | EP | disclosed |
| WO-1989005452-A1 | MEASUREMENT OF PGE2 (PROSTAGLANDIN E2) LEVELS IN PATIENTS WITH CHRONIC INFLAMMATORY BOWEL DISEASE | FONDEN FOR PROSTAGLANDINFORSKNING (DK) | 1989-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | SMAD3, SMAD2, SOST | ALDH1A1 4038/4885TDP1 2520/4885HSD17B10 2970/4885 |
| US-20070167416-A1 | Administering 5-aminosalicylate (balsalazide) with food increases bioavailability; label on container recommends to take drug with food; inflammatory bowel disease, radiation enteritis, colon cancer; gastrointestinal disorders | IL5, CYP3A5, APC | ALDH1A1 353/4885TDP1 4292/4885HSD17B10 4081/4885 |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | SMAD3, SMAD2, SOST | ALDH1A1 3968/4885TDP1 2621/4885HSD17B10 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.